Zimmer Biomet (ZBH)
Makes joint-replacement implants and robotic systems for orthopedic surgery.
Something off on this page? Send us feedback.
Sells knee and hip replacement systems alongside sports-medicine, trauma, foot-and-ankle, and other orthopedic products, earning revenue through direct hospital and surgery-center accounts and distributors. Its implant franchises are paired with ROSA robotics and the ZBEdge digital platform, while the Americas remain its largest region.
Designs and manufactures knee and hip replacement systems, sports-medicine and biologic products, trauma and extremity implants, foot-and-ankle devices, craniomaxillofacial and thoracic products, bone cement, and surgical tools. The ZBEdge platform connects ROSA robotics and other digital technologies with implant workflows and data gathered before, during, and after surgery.
Pairs broad reconstructive implant franchises with the instruments, clinical training, consigned inventory, and technical sales support needed around surgical procedures. Hospitals and ambulatory surgery centers buy directly or through distributors across the Americas, EMEA, and Asia Pacific, with the Americas the largest region. Demand and pricing depend on procedure volumes, reimbursement and healthcare cost controls, while product launches require regulatory clearance and reliable component supply.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Aug 10, 2026 | Canaccord Genuity | Reiterate | Rating: —Target: $83 | Target: $100 |
| Aug 6, 2026 | Truist Financial | Target | Target: $92 | Target: $106 |
| Aug 6, 2026 | Robert W. Baird | Target | Target: $92 | Target: $104 |
| Aug 6, 2026 | UBS | Reiterate | Rating: —Target: $115 | Target: $120 |
| Aug 6, 2026 | Bernstein | Reiterate | Rating: —Target: $99 | Target: $93 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $410.0M · Total debt $7.48B · Total assets $22.80B · Shareholders' equity $12.62B
- Revenue
- $2.18B
- Operating income
- $326.1M
- Net income
- $198.3M
HistoryDividendAnnual yieldUpcoming
| Institutions | ≥ 97.14% | 185.28M shares | |
|---|---|---|---|
| 931 holders · as of Jun 30, 2026 · largest filers only | |||
| Insiders | 5.80% | 11.06M shares | |
| 11 holders · as of Sep 9, 2026 | |||
| Adds to | 102.94% | ||
190.74M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the 100 largest filers, so at least this.
These groups come from separate filings that can overlap, so they add to 102.94%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Dodge & CoxInstitution | 12.65% | 24.12M | as of Jun 30, 2026 |
BlackRock, Inc.Institution | 8.19% | 15.61M | as of Jun 30, 2026 |
Harris Associates L PInstitution | 6.68% | 12.74M | as of Jun 30, 2026 |
Vanguard Capital Management LLCInstitution | 6.62% | 12.63M | as of Jun 30, 2026 |
Capital International InvestorsInstitution | 6.39% | 12.18M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Sep 11, 2026 | Kevin R. Thornal | officer: Grp Pres-Global Business | −5,691 | $92.95 |
| Sep 4, 2026 | Chad F. Phipps | officer: See remarks below. | −3,000 | $98.35 |
| May 29, 2026 | Sang Yi | officer: Group President, Asia Pacific | −5,000 | $82.64 |
| Mar 12, 2026 | Lori Winkler | officer: SVP and CHRO | −2,650 | $94.66 |
| Feb 12, 2026 | Sang Yi | officer: Group President, Asia Pacific | −1,000 | $96.49 |
- Stryker
Largest direct rival in knees, hips, trauma, S.E.T., and Mako robotics.
- Johnson & Johnson
Broad orthopedic rival via DePuy Synthes — knees, hips, trauma, robotics, CMF.
- Smith & Nephew (ADR)
Global #4 orthopedics; CORI robotics rivals ROSA in knees, hips, sports med.
- Enovis
DJO-heritage rival in extremities, foot & ankle, shoulder, and knee bracing.
- Globus Medical
Post-NuVasive spine leader expanding into trauma and robotic knee vs ZBH S.E.T.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Zimmer Biomet | $94.60 | +0.29% | $18.25B | 22.9 | 10.8 | 2.1 | +4.8% |
| Stryker | $276.42 | +0.81% | $105.11B | 28.4 | 17.3 | 4.1 | +9.4% |
| Johnson & Johnson | $267.53 | −0.72% | $649.40B | 31.2 | 22.5 | 6.6 | +6.6% |
| Smith & Nephew (ADR) | $27.66 | −0.13% | $11.63B | 19.0 | — | 1.8 | +4.6% |
| Enovis | $18.37 | +1.83% | $1.04B | — | 5.1 | 0.5 | +3.2% |
| Globus Medical | $74.80 | +0.69% | $10.02B | 19.1 | 14.6 | 3.2 | +5.9% |
| Median | 23.8 | 15.9 | 3.2 | +5.9% |